Investegate |PureTech Health PLC Announcements | PureTech Health PLC: LYT-100 Advances to Phase 2a Study in Lymphedema
Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in patients with breast-cancer related, upper limb secondary lymphedema Previously announced results from multiple ascending dose and food effect study in healthy volunteers demonstrated favorable tolerability and pharmacokinetic proof-of-concept for LYT-100 A separate Phase 2 study evaluating LYT-100 in Long COVID respiratory complications and related sequelae was recently initiated PureTech Health plc (LSE: PR...
Source: investegate.co.uk